MDS, the Toronto-based parent company of Canadian medical isotope supplier MDS Nordion, reported that its Life Sciences division, which includes MDS Nordion, had fiscal 2003 fourth-quarter revenues of $275 million, Canadian ($207.2 million) a downturn from the $283 million, CAD ($213.2 million) posted for the same period in 2002.
For the quarter (end-October 31), operating income for the Life Sciences segment, excluding restructuring charges of $19 million, CAD ($14.3 million) for the period, was $51 million, CAD ($38.4 million), up 13% compared with $45 million, CAD ($33.9 million) in the fourth quarter of 2002, the company said.
Revenues for the isotope business were down $12 million this quarter relative to last year, reflecting the impact of the sale of the company’s oncology software solutions business, which generated $10 million in the fourth quarter of last year, as well as a strong fourth quarter in its cobalt business in 2002, MDS said.
For the 2003 fiscal year, the company reported Life Sciences segment revenues of $1.083 billion, CAD ($815.8 million), an increase of 3% compared with revenues of $1.053 billion, CAD ($793.1 million) in fiscal 2002. Operating income for the year, including restructuring charges, was $192 million, CAD ($144.6 million), a slight downturn compared with the $205 million, CAD ($154.4 million) reported for fiscal 2002.
By AuntMinnie.com staff writersDecember 11, 2003
Related Reading
MDS revamps for Q4, October 29, 2003
MDS records Q3 uptick in Life Sciences group, September 4, 2003
MDS Nordion inks licensing deal, August 12, 2003
MDS Nordion brings new cyclotron online, June 17, 2003
MDS sells oncology software unit to Delft, February 11, 2003
Copyright © 2003 AuntMinnie.com
